The webinar will feature a presentation by Infectious Diseases experts David van Duin, M.D., Ph.D., F.I.D.S.A., F.A.S.T. (University of North Carolina at Chapell Hill) and Michael J. Rybak, Pharm.D., M.P.H., Ph.D. (Wayne State University) who will discuss the burden and current treatment landscape of Acinetobacter infections. Drs. van Duin and Rybak will be available to answer questions following the formal presentations.

Entasis’ management team will also give an update on their pipeline product sulbactam-durlobactam (SUL-DUR), an antibiotic consisting of sulbactam, a safe and well tolerated β-lactam with intrinsic activity against Acinetobacter, with durlobactam, a novel, comprehensive potent inhibitor of Class A, C, and D β-lactamases that restores the activity of sulbactam. Sulbactam-durlobactam has just completed enrollment of a global Phase 3 registrational clinical trial (ATTACK) to treat infections caused by Acinetobacter baumannii, including carbapenem-resistant strains. Sulbactam-durlobactam has been designated a Qualified Infectious Disease Product (QIDP) by the U.S. Food and Drug Administration and awarded Fast Track status.